MiR‐101 inhibits ovarian carcinogenesis by repressing the expression of brain‐derived neurotrophic factor

Abstract

Ovarian cancer is one of the most lethal malignant gynecological tumors as a result of difficulties in early‐stage detection and a lack of effective treatments for patients with advanced or recurrent cancer. In the present study, we aimed to explore whether some of the micro RNA (mi RNA ) content of serum might be related to ovarian cancer, as well as the role of these mi RNA s and their intercellular transport via exosomes in ovarian cancer. We first detected the expression of six candidate mi RNA s in ovarian cancer tissues and adjacent nontumor ovarian samples from 36 patients and confirmed the altered expression of four mi RNA s. The level of these six candidate mi RNA s was also examined in exosomes from patient serum samples. Only the level of miR‐101 was altered in both ovarian tissue samples and serum exosomes. After prediction using online bioinformatics tools and confirmation by dual‐luciferase assay and immunoblotting, we identified that miR‐101 can repress the expression of brain‐derived neurotrophic factor by targeting its 3′‐ UTR . Using Transwell assays, we examined the effect of miR‐101 on migration and invasion capacity of ovarian cancer cells. The results indicated that the reduction of miR‐101 is mostly related to significant enhanced ovarian cancer cell migration. Thus, the results of the present study indicate that miR‐101 content in serum exosomes has potential as a marker for diagnosis of ovarian cancer and that miR‐101 mimics are potential therapeutic drugs for the treatment of ovarian cancer.

Neurotrophin Signaling in Medulloblastoma

“…NTRK1 fusions are now known to occur in many other solid tumor types, including lung adenocarcinoma, papillary thyroid carcinoma, secretory breast carcinoma, and glioblastoma (GBM) [ 45 , 46 ]. In addition, evidence indicating that NGF/TrkA, BDNF/TrkB, TrkC, or p75NTR play a role in cancer has rapidly accumulated over the past few years, with most studies showing that neurotrophins and their receptors are expressed in cancer cells and influence experimental tumor growth, cellular survival, proliferation, migration, invasion, neovascularization, metastasis, and treatment resistance in many peripheral solid tumor types including colorectal, breast, small cell and non-small cell lung, cervical, bladder, gallbladder, laryngeal, renal, head and neck, and oral squamous cell cancers [ 3 , 5 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 ].…”

Circulating Extracellular Vesicles in Gynecological Tumors: Realities and Challenges

“…Xu et al have identified an alteration in miR101 levels in tissue samples and serum exosomes from patients with OC. Their results indicate that a decrease in miR101 in serum exosomes may serve as potential diagnostic biomarker in OC ( 79 ). In addition, high levels of EV-associated miR-99a-5p have been detected in serum from patients with OC and correlated with the promotion of invasion by regulating human peritoneal mesothelial cells (HPMCs) through vitronectin and fibronectin ( 80 ).…”

Circulating non-coding RNAs in recurrent and metastatic ovarian cancer

“…HPMCs transfected with miR-99a-5p promoted OC invasion and exhibited increased expression levels of fibronectin and vitronectin. Xu et al [138] found that the levels of miR-101 were altered in serum exosomes as well as in tissue samples. Using dual-luciferase assay and immunoblotting, they showed that miR-101 could repress the expression of brain-derived neurotrophic factor (BDNF) by targeting its 3'-UTR.…”